Olverembatinib (HQP-1351)
Revision as of 16:31, 7 September 2023 by Jwarner (talk | contribs) (Jwarner moved page Olverembatinib (HQP1351) to Olverembatinib (HQP-1351): naming standardization)
Mechanism of action
Third-generation TKI
Diseases for which it is used
History of changes in NMPA indication
- 2021-11: Initial conditional approval for the treatment of adult patients with TKI-resistant CML-CP or CML-AP harboring the T315I mutation as confirmed by a validated diagnostic test. (Based on HQP1351CC203)
Also known as
- Code name: HQP-1351